Association of Semaglutide Treatment With Liver Cirrhosis and Hepatocellular Carcinoma in Type 2 Diabetes: A Population‐Based Cohort Study

Key Points

• To investigate the association between semaglutide treatment and the risk of liver cirrhosis and hepatocellular carcinoma in individuals with type 2 diabetes.
• Population-based cohort study design
• Included adults with type 2 diabetes
• Evaluated incidence of liver cirrhosis and hepatocellular carcinoma during treatment
• Semaglutide treatment did not reduce the risk of liver cirrhosis
• Semaglutide treatment was not linked to a lower incidence of hepatocellular carcinoma

Abstract